Amnon Hoffman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1865484/publications.pdf

Version: 2024-02-01

63	2,883	236833	175177
papers	citations	25 h-index	52 g-index

70	70	70	3003
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Strategies for enhancing the oral bioavailability of cannabinoids. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 313-322.	1.5	5
2	Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: InÂVivo Investigations in Pigs. Journal of Pharmaceutical Sciences, 2021, 110, 1824-1833.	1.6	3
3	On the Suitability of Porcine Labial Mucosa as a Model for Buccal Mucosal Drug Delivery Research. Journal of Pharmaceutical Sciences, 2021, 110, 1863-1864.	1.6	1
4	Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of Î±4Î²1 (VLA-4)/Î±9Î²1 Integrin for Therapy of Multiple Sclerosis. Jacs Au, 2021, 1, 2361-2376.	3.6	2
5	Novel humanin analogs confer neuroprotection and myoprotection to neuronal and myoblast cell cultures exposed to ischemia-like and doxorubicin-induced cell death insults. Peptides, 2020, 134, 170399.	1.2	7
6	Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs. Frontiers in Chemistry, 2020, 8, 532577.	1.8	4
7	Using the Absorption Cocktail Approach to Assess Differential Absorption Kinetics of Cannabidiol Administered in Lipid-Based Vehicles in Rats. Molecular Pharmaceutics, 2020, 17, 1979-1986.	2.3	12
8	Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study. Journal of Pharmaceutical Sciences, 2020, 109, 2729-2734.	1.6	9
9	The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats. International Journal of Pharmaceutics, 2020, 580, 119201.	2.6	62
10	The effect of piperine on oral absorption of cannabidiol following acute vs. chronic administration. European Journal of Pharmaceutical Sciences, 2020, 148, 105313.	1.9	15
11	Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 108-115.	2.0	37
12	Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. International Journal of Pharmaceutics, 2020, 581, 119276.	2.6	29
13	Investigation of cannabidiol gastro retentive tablets based on regional absorption of cannabinoids in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 229-235.	2.0	11
14	A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states. Expert Opinion on Drug Delivery, 2019, 16, 1031-1035.	2.4	22
15	Myristoylation Confers Oral Bioavailability and Improves the Bioactivity of c(MyD 4â€“4), a Cyclic Peptide Inhibitor of MyD88. Molecular Pharmaceutics, 2019, 16, 1516-1522.	2.3	6
16	PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Journal of Pharmaceutical Sciences, 2018, 107, 1423-1429.	1.6	70
17	The Effect of Piperine Pro-Nano Lipospheres on Direct Intestinal Phase II Metabolism: The Raloxifene Paradigm of Enhanced Oral Bioavailability. Molecular Pharmaceutics, 2018, 15, 1548-1555.	2.3	21
18	Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. Molecular Pharmaceutics, 2018, 15, 3468-3477.	2.3	27

#	Article	IF	Citations
19	Oral aktive Peptide: Gibt es ein Patentrezept?. Angewandte Chemie, 2018, 130, 14614-14640.	1.6	15
20	Orally Active Peptides: Is There a Magic Bullet?. Angewandte Chemie - International Edition, 2018, 57, 14414-14438.	7.2	118
21	Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88. Scientific Reports, 2018, 8, 9476.	1.6	14
22	Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrinâ€…Î±vÎ²3. Angewandte Chemie - International Edition, 2017, 56, 16405-16409.	7.2	30
23	LÃ¶sung des Problems mangelnder oraler VerfÃ¼gbarkeit cyclischer Hexapeptide: Entwicklung eines selektiven, oral verfÃ¼gbaren Liganden fÃ¼r das Integrinâ€…Î±vÎ²3. Angewandte Chemie, 2017, 129, 16624-16629.	1.6	5
24	Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. Journal of Controlled Release, 2017, 266, 1-7.	4.8	77
25	The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. European Journal of Pharmaceutical Sciences, 2017, 109, 21-30.	1.9	75
26	cisâ€Peptide Bonds: A Key for Intestinal Permeability of Peptides?. Chemistry - A European Journal, 2015, 21, 15148-15152.	1.7	33
27	Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opinion on Drug Delivery, 2015, 12, 1121-1133.	2.4	116
28	Superiority of the S,S conformation in diverse pharmacological processes: Intestinal transport and entry inhibition activity of novel anti-HIV drug lead. International Journal of Pharmaceutics, 2015, 495, 660-663.	2.6	3
29	Improved Oral Bioavailability of BCS Class 2 Compounds by Self Nano-Emulsifying Drug Delivery Systems (SNEDDS): The Underlying Mechanisms for Amiodarone and Talinolol. Pharmaceutical Research, 2013, 30, 3029-3044.	1.7	82
30	Intestinal Permeability of Cyclic Peptides: Common Key Backbone Motifs Identified. Journal of the American Chemical Society, 2012, 134, 12125-12133.	6.6	176
31	Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chemistry and Physics of Lipids, 2012, 165, 438-453.	1.5	77
32	Variation of Population Release Kinetics in Polydisperse Multiparticulate Systems (Microcapsules,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 of Individuals. Journal of Pharmacy and Pharmacology, 2011, 40, 93-96.	1.2	27
33	The Effect of Multiple N-Methylation on Intestinal Permeability of Cyclic Hexapeptides. Molecular Pharmaceutics, 2011, 8, 479-487.	2.3	130
34	Microencapsulation of paracetamol using polyacrylate resins (Eudragit Retard), kinetics of drug release and evaluation of kinetic model. Journal of Pharmacy and Pharmacology, 2011, 37, 391-395.	1.2	38
35	The Calbindin-D28k binding site on inositol monophosphatase may allow inhibition independent of the lithium site of action. Nature Precedings, 2011, , .	0.1	0
36	Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opinion on Drug Discovery, 2010, 5, 655-671.	2.5	56

#	Article	IF	Citations
37	Implications on Emergence of Antimicrobial Resistance as a Critical Aspect in the Design of Oral Sustained Release Delivery Systems of Antimicrobials. Pharmaceutical Research, 2008, 25, 667-671.	1.7	14
38	Structureâ€activity relationship and metabolic stability studies of backbone cyclization and Nâ€methylation of melanocortin peptides. Biopolymers, 2008, 90, 671-682.	1.2	47
39	Improving Oral Bioavailability of Peptides by Multiple Nâ€Methylation: Somatostatin Analogues. Angewandte Chemie - International Edition, 2008, 47, 2595-2599.	7.2	310
40	N-Methylation of Peptides: A New Perspective in Medicinal Chemistry. Accounts of Chemical Research, 2008, 41, 1331-1342.	7.6	472
41	Eligen insulin--a system for the oral delivery of insulin for diabetes. IDrugs: the Investigational Drugs Journal, 2008, 11, 433-41.	0.7	3
42	Effect of Structural and Conformation Modifications, Including Backbone Cyclization, of Hydrophilic Hexapeptides on Their Intestinal Permeability and Enzymatic Stability. Journal of Medicinal Chemistry, 2007, 50, 6201-6211.	2.9	79
43	Prolonged-Release Ciprofloxacin. American Journal of Drug Delivery, 2006, 4, 121.	0.6	0
44	Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. European Journal of Pharmaceutical Sciences, 2005, 25, 307-312.	1.9	32
45	Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. International Journal of Pharmaceutics, 2004, 277, 141-153.	2.6	103
46	Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers. Journal of Clinical Pharmacology, 2003, 43, 711-720.	1.0	49
47	Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine. Pharmaceutical Research, 2001, 18, 1220-1225.	1.7	7
48	Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin. Endocrinology, 2001, 142, 477-486.	1.4	76
49	The Effect of Cimetidine on the Pharmacodynamics of Theophyllineâ€Induced Seizures and Ethanol Hypnotic Activity. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 130-132.	0.0	2
50	Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug. Pharmaceutical Research, 1999, 16, 1093-1097.	1.7	6
51	Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharmaceutical Research, 1999, 16, 1399-1406.	1.7	19
52	The Anticonvulsant Effect of Deprenyl on Pentylenetetrazol-Induced Seizures in Lewis Rats. International Journal of Neuroscience, 1997, 90, 223-232.	0.8	4
53	Pharmacokinetic Considerations of New Insulin Formulations and Routes of Administration. Clinical Pharmacokinetics, 1997, 33, 285-301.	1.6	106
54	Pharmacodynamics of phenobarbital anesthesia and pentylenetetrazol-induced maximal seizures in a rat model of neoplastic spinal cord compression. Pharmaceutical Research, 1994, 11, 536-540.	1.7	1

#	Article	IF	Citations
55	The effect of immunosuppression by total-body irradiation on the pharmacodynamics of centrally active drugs in rats. Pharmaceutical Research, 1994, 11, 704-708.	1.7	1
56	A new route of drug administration: intrauterine delivery of insulin and calcitonin. Pharmaceutical Research, 1993, 10, 828-833.	1.7	25
57	High-dose methotrexate does not affect the pharmacodynamics of phenobarbital hypnotic action but decreases the central nervous system (CNS) sensitivity to pentylenetetrazol-induced maximal seizures in rats. Pharmaceutical Research, 1992, 09, 1295-1298.	1.7	3
58	Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. Pharmaceutical Research, 1992, 09, 1018-1023.	1.7	10
59	Kinetics of drug action in disease states. XL. Effect of the dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats. Pharmaceutical Research, 1991, 08, 415-417.	1.7	3
60	Kinetics of drug action in disease states. XXXIX. Effect of orally administered activated charcoal on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline administered intravenously to rats with renal failure. Pharmaceutical Research, 1990, 07, 242-246.	1.7	8
61	Gender differences in the pharmacodynamics of barbiturates in rats. Pharmaceutical Research, 1989, 06, 976-981.	1.7	6
62	Relation between individual and ensemble release kinetics of indomethacin from microspheres. Pharmaceutical Research, 1988, 05, 178-182.	1.7	19
63	Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin. , 0, .		22